Lixte Biotech Finalizes Nomad Acquisition, Issuing Up to 53.5M Shares in Highly Dilutive Deal
LIXT has more than doubled off its 52-week low of $0.64 on elevated volume (5.8× avg).
Summary
Lixte Biotechnology has entered a definitive agreement to acquire Nomad Transportable Power Systems. This stock-for-stock transaction involves issuing up to 53.5 million shares, comprising 50.5 million shares of convertible preferred stock (convertible at $1.00 per common share) and 3 million common shares. This acquisition completes Lixte's strategic pivot from cancer drug development to AI energy infrastructure, a shift announced earlier this month following a 'going concern' warning and clinical trial issues. The issuance of up to 53.5 million new shares represents massive dilution for existing shareholders, potentially increasing the share count by over 300%. Closing conditions include Lixte having at least $16.5 million in unrestricted cash and stockholder approval for the preferred stock conversion.
At the time of this announcement, LIXT was trading at $6.88 on NASDAQ in the Technology sector, with a market capitalization of approximately $119.6M. The 52-week trading range was $0.64 to $7.51. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.